Peer-Reviewed Journal Details
Mandatory Fields
Whyte, W;Roche, ET;Varela, CE;Mendez, K;Islam, S;O'Neill, H;Weafer, F;Shirazi, RN;Weaver, JC;Vasilyev, NV;McHugh, PE;Murphy, B;Duffy, GP;Walsh, CJ;Mooney, DJ
2018
June
Nature Biomedical Engineering
Sustained release of targeted cardiac therapy with a replenishable implanted epicardial reservoir
Published
Altmetric: 136WOS: 4 ()
Optional Fields
MESENCHYMAL STEM-CELLS ACUTE MYOCARDIAL-INFARCTION HEART-FAILURE PARACRINE MECHANISMS PROGENITOR CELLS FUNCTIONAL IMPROVEMENT ISCHEMIC-MYOCARDIUM CHITOSAN HYDROGEL DRUG-DELIVERY STROMAL CELLS
2
416
428
The clinical translation of regenerative therapy for the diseased heart, whether in the form of cells, macromolecules or small molecules, is hampered by several factors: the poor retention and short biological half-life of the therapeutic agent, the adverse side effects from systemic delivery, and difficulties with the administration of multiple doses. Here, we report the development and application of a therapeutic epicardial device that enables sustained and repeated administration of small molecules, macromolecules and cells directly to the epicardium via a polymer-based reservoir connected to a subcutaneous port. In a myocardial infarct rodent model, we show that repeated administration of cells over a four-week period using the epicardial reservoir provided functional benefits in ejection fraction, fractional shortening and stroke work, compared to a single injection of cells and to no treatment. The pre-clinical use of the therapeutic epicardial reservoir as a research model may enable insights into regenerative cardiac therapy, and assist the development of experimental therapies towards clinical use.
2157-846X
10.1038/s41551-018-0247-5
Grant Details
Publication Themes